Name | Number of supported studies | Average coverage | |
---|---|---|---|
GABAergic neuron | 3 studies | 31% ± 6% | |
glutamatergic neuron | 3 studies | 29% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 25% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 1180.42 | 2630 / 2642 | 100% | 28.01 | 703 / 705 |
thymus | 100% | 977.83 | 651 / 653 | 89% | 9.46 | 538 / 605 |
kidney | 99% | 715.29 | 88 / 89 | 88% | 10.50 | 790 / 901 |
uterus | 100% | 2419.31 | 170 / 170 | 68% | 8.33 | 311 / 459 |
lung | 95% | 521.56 | 548 / 578 | 69% | 7.38 | 800 / 1155 |
adrenal gland | 84% | 359.37 | 216 / 258 | 80% | 11.08 | 183 / 230 |
breast | 99% | 950.86 | 454 / 459 | 56% | 2.92 | 625 / 1118 |
bladder | 100% | 1802.24 | 21 / 21 | 51% | 5.62 | 256 / 504 |
esophagus | 91% | 649.92 | 1314 / 1445 | 58% | 7.21 | 106 / 183 |
skin | 71% | 900.64 | 1287 / 1809 | 74% | 11.82 | 347 / 472 |
prostate | 97% | 900.91 | 238 / 245 | 32% | 1.36 | 159 / 502 |
ovary | 100% | 1579.01 | 180 / 180 | 27% | 1.37 | 114 / 430 |
intestine | 87% | 882.02 | 842 / 966 | 18% | 1.24 | 94 / 527 |
blood vessel | 100% | 1382.92 | 1335 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 1231.88 | 1195 / 1204 | 0% | 0 | 0 / 0 |
stomach | 68% | 356.95 | 243 / 359 | 28% | 1.74 | 79 / 286 |
eye | 0% | 0 | 0 / 0 | 95% | 12.95 | 76 / 80 |
liver | 56% | 179.69 | 127 / 226 | 38% | 2.95 | 154 / 406 |
pancreas | 15% | 41.06 | 48 / 328 | 78% | 5.48 | 139 / 178 |
muscle | 90% | 520.52 | 720 / 803 | 0% | 0 | 0 / 0 |
heart | 87% | 516.78 | 752 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 76% | 9.41 | 22 / 29 |
tonsil | 0% | 0 | 0 / 0 | 71% | 7.72 | 32 / 45 |
spleen | 46% | 131.64 | 110 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 20% | 2349.10 | 185 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007605 | Biological process | sensory perception of sound |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0012501 | Biological process | programmed cell death |
GO_0055085 | Biological process | transmembrane transport |
GO_0002839 | Biological process | positive regulation of immune response to tumor cell |
GO_0042491 | Biological process | inner ear auditory receptor cell differentiation |
GO_2001244 | Biological process | positive regulation of intrinsic apoptotic signaling pathway |
GO_0070269 | Biological process | pyroptotic inflammatory response |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0098586 | Biological process | cellular response to virus |
GO_0071356 | Biological process | cellular response to tumor necrosis factor |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005546 | Molecular function | phosphatidylinositol-4,5-bisphosphate binding |
GO_0022829 | Molecular function | wide pore channel activity |
GO_1901612 | Molecular function | cardiolipin binding |
GO_0005515 | Molecular function | protein binding |
Gene name | GSDME |
Protein name | Gasdermin-E (Inversely correlated with estrogen receptor expression 1) (ICERE-1) (Non-syndromic hearing impairment protein 5) [Cleaved into: Gasdermin-E, N-terminal (GSDME-NT); Gasdermin-E, C-terminal (GSDME-CT)] DFNA5 protein Deafness, autosomal dominant 5 Gasdermin E |
Synonyms | ICERE1 DFNA5 |
Description | FUNCTION: [Gasdermin-E]: Precursor of a pore-forming protein that converts non-inflammatory apoptosis to pyroptosis . This form constitutes the precursor of the pore-forming protein: upon cleavage, the released N-terminal moiety (Gasdermin-E, N-terminal) binds to membranes and forms pores, triggering pyroptosis . .; FUNCTION: [Gasdermin-E, N-terminal]: Pore-forming protein produced by cleavage by CASP3 or granzyme B (GZMB), which converts non-inflammatory apoptosis to pyroptosis or promotes granzyme-mediated pyroptosis, respectively . After cleavage, moves to the plasma membrane, homooligomerizes within the membrane and forms pores of 10-15 nanometers (nm) of inner diameter, allowing the release of mature interleukins (IL1B and IL16) and triggering pyroptosis . Binds to inner leaflet lipids, bisphosphorylated phosphatidylinositols, such as phosphatidylinositol (4,5)-bisphosphate . Cleavage by CASP3 switches CASP3-mediated apoptosis induced by TNF or danger signals, such as chemotherapy drugs, to pyroptosis . Mediates secondary necrosis downstream of the mitochondrial apoptotic pathway and CASP3 activation as well as in response to viral agents . Exhibits bactericidal activity . Cleavage by GZMB promotes tumor suppressor activity by triggering robust anti-tumor immunity . Suppresses tumors by mediating granzyme-mediated pyroptosis in target cells of natural killer (NK) cells: cleavage by granzyme B (GZMB), delivered to target cells from NK-cells, triggers pyroptosis of tumor cells and tumor suppression . May play a role in the p53/TP53-regulated cellular response to DNA damage . .; FUNCTION: [Gasdermin-E, N-terminal]: (Microbial infection) Pore-forming protein, which promotes maternal placental pyroptosis in response to Zika virus infection, contributing to adverse fetal outcomes. . |
Accessions | A4FVA8 H7C0L2 A4FTY0 ENST00000409970.6 [O60443-3] H7C147 ENST00000419307.6 [O60443-3] ENST00000415480.5 ENST00000430096.1 ENST00000645220.1 [O60443-1] H7BZJ0 ENST00000446822.6 C9JSR4 ENST00000414428.2 O60443 ENST00000342947.9 [O60443-1] |